REGENXBIO Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held on May 29, 2026, and the commencement of a Stock Option Exchange Program for non-executive employees on June 3, 2026. The filing covers voting results for five proposals and details the terms of the newly initiated equity program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity program administration rather than financial performance.
Material Changes and Voting Results
Approximately 82.95% of entitled shares (42,818,883 shares) were represented at the Annual Meeting. Key voting outcomes include:
- Proposal 1 (Director Elections): All three Class II nominees (Jean Bennett, A.N. "Jerry" Karabelas, and Daniel Tassé) were elected.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP.
- Proposal 3 (Executive Compensation): Advisory approval was granted for named executive officer compensation.
- Proposal 4 (Non-Executive Option Exchange): Stockholders approved a Stock Option Exchange Program for non-executive employees.
- Proposal 5 (Executive Option Exchange): Stockholders did not approve a Stock Option Exchange Program for executive employees.
Outlook, Management Commentary, and Unusual Items
Following the shareholder approval of Proposal 4, the Company commenced the Stock Option Exchange Program for non-executive employees on June 3, 2026. The program allows eligible participants to exchange outstanding options with an exercise price at or above $18.00 for new options at a reduced exercise price (fair market value on the new grant date). The exchange period is scheduled to conclude on July 1, 2026, unless extended. Management stated the program is not expected to result in a significant change to the Company's stock compensation expense. The rejection of the similar program for executive employees (Proposal 5) represents a notable divergence in shareholder sentiment regarding executive equity incentives.
Investor Verification Checklist
- Verify the specific terms of the Stock Option Exchange Program in the upcoming Tender Offer Statement expected to be filed on June 3, 2026.
- Review the definitive Proxy Statement filed on April 14, 2026, for detailed rationale behind the rejected executive option exchange program.
- Monitor the Company's stock price relative to the $18.00 threshold to assess the potential participation rate of non-executive employees.
- Confirm the final impact on stock-based compensation expense once the exchange program concludes.